Download PDF
Open Access
CC BY 4.0 · Endosc Int Open 2025; 13: a26763883
DOI: 10.1055/a-2676-3883
Original article

Post-endoscopy esophageal adenocarcinoma and root cause analysis in Auckland, New Zealand

Authors

  • Seong Shin

    1   Gastroenterology, Te Whatu Ora Health New Zealand Waitemata, Auckland, New Zealand (Ringgold ID: RIN1406)

  • Dongyeon Kang

    1   Gastroenterology, Te Whatu Ora Health New Zealand Waitemata, Auckland, New Zealand (Ringgold ID: RIN1406)

  • Russell S Walmsley

    2   Gastroenterology, North Shore Hospital, Auckland, New Zealand (Ringgold ID: RIN1403)
    3   Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand (Ringgold ID: RIN62710)
Further Information
Also available at
  Permissions and Reprints

Abstract

Background and study aims

Post-endoscopy esophageal adenocarcinomas (PEEC) challenge timely diagnosis of esophageal adenocarcinomas (OAs). This study aimed to determine prevalence of PEECs in Auckland region and elucidate the most plausible causes through a root-cause analysis framework.

Patients and methods

OA cases diagnosed in Auckland from 2013 to 2022 were retrieved from the New Zealand Cancer Registry (NZCR). Electronic clinical data were collected via the Regional Clinical Portal software. The primary outcome was PEEC prevalence, defined as OA diagnosed 6 to 36 months following an esophagogastroduodenoscopy (EGD) that failed to detect the cancer. Identified PEECs were classified into six categories.

Results

Among 633 OA cases, 45 (7.1%) were PEECs. A higher prevalence of PEEC was observed in patients with Barrett’s esophagus (BE) (18.1% vs 2.7%), undergoing surveillance EGDs (52.6% vs 3.6%) and with early-stage cancers. Root-cause analysis delineated the PEEC causes, classified as follows: A (17.8%): lesion was identified, endoscopic assessment was adequate, follow-up was appropriately planned and executed, yet PEEC developed; B (17.8%): follow-up was delayed due to administrative factors; C (22.2%): follow-up decisions were inappropriate; D (22.2%): inadequate endoscopic assessment; E (11.1%): lesion was unidentified despite adequate assessment; and F (8.9%): lesion was unidentified and assessment was inadequate. Categories B, C, D, and F comprised 71.1% of cases deemed potentially avoidable.

Conclusions

Auckland’s PEEC prevalence aligns with international post-endoscopy upper gastrointestinal cancer rates. Root-cause analysis underscores that a significant proportion of PEECs may be preventable with improved clinical practice.

Keywords

Endoscopy Upper GI Tract - Barrett's and adenocarcinoma - Precancerous conditions & cancerous lesions (displasia and cancer) stomach - Malignant strictures


Publication History

Received: 06 January 2025

Accepted after revision: 31 July 2025

Accepted Manuscript online:
04 August 2025

Article published online:
30 September 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/).

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

Bibliographical Record
Seong Shin, Dongyeon Kang, Russell S Walmsley. Post-endoscopy esophageal adenocarcinoma and root cause analysis in Auckland, New Zealand. Endosc Int Open 2025; 13: a26763883.
DOI: 10.1055/a-2676-3883
 

  • References

  • 1 Ferlay J, Shin HR, Bray F. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917
    Search in Google Scholar
  • 2 New Zealand Cancer Registry (NZCR). Cancer registration statistics. Wellington: Ministry of Health NZ. https://www.health.govt.nz/nz-health-statistics/national-collections-and-surveys/collections/new-zealand-cancer-registry-nzcr
  • 3 American Cancer Society. Esophagus Cancer. https://www.cancer.net/cancer-types/esophageal-cancer
  • 4 Kamel M, Lee B, Rahouma M. et al. T1N0 oesophageal cancer: patterns of care and outcomes over 25 years. Eur J Cardiothorac Surg 2017; 53: 952-959
    Search in Google Scholar
  • 5 Lightdale CJ. Esophageal Cancer. Am J Gastroenterol 1999; 94 (01) 20-29
    Search in Google Scholar
  • 6 Januszewicz W, Witczak K, Wieszczy P. et al. Prevalence and risk factors of upper gastrointestinal cancers missed during endoscopy: a nationwide registry-based study. Endoscopy; 2022; 54: 653-660
    Search in Google Scholar
  • 7 Kamran U, King D, Abbasi A. et al. A root cause analysis system to establish the most plausible explanation for post-endoscopy upper gastrointestinal cancer. Endoscopy 2023; 55: 109-118
    Search in Google Scholar
  • 8 Menon S, Trudgill N. How commonly is upper gastrointestinal cancer missed at endoscopy? A meta-analysis. Endosc Int Open 2014; 2: E46-E50
    Search in Google Scholar
  • 9 Chadwick G, Groene O, Hoare J. et al. A population-based, retrospective, cohort study of esophageal cancer missed at endoscopy. Endoscopy 2014; 46: 553-560
    Search in Google Scholar
  • 10 Chadwick G, Groene O, Riley S. et al. Gastric cancers missed during endoscopy in England. Clin Gastroenterol Hepatol 2015; 13: 1264-1270
    Search in Google Scholar
  • 11 Pimenta-Melo AR, Monteiro-Soares M, Libânio D. et al. Missing rate for gastric cancer during upper gastrointestinal endoscopy: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2016; 28: 1041-1049
    Search in Google Scholar
  • 12 Cheung D, Menon S, Hoare J. et al. Factors associated with upper gastrointestinal cancer occurrence after endoscopy that did not diagnose cancer. Dig Dis Sci 2016; 61: 2674-2684
    Search in Google Scholar
  • 13 Alexandre L, Tsilegeridis-Legeris T, Lam S. Clinical and endoscopic characteristics associated with post-endoscopy upper gastrointestinal cancers: a systematic review and meta-analysis. Gastroenterology 2022; 162: 1123-1135
    Search in Google Scholar
  • 14 Naini BV, Souza RF, Odze RD. Barrett’s esophagus: A comprehensive and contemporary review for pathologists. Am J Surg Pathol 2016; 40: e45-e66
    Search in Google Scholar
  • 15 Klaver E, Bureo Gonzalez A, Mostafavi N. et al. Barrett’s esophagus surveillance in a prospective Dutch multi-center community-based cohort of 985 patients demonstrates low risk of neoplastic progression. United European Gastroenterol J 2021; 9: 929-937
    Search in Google Scholar
  • 16 Wani S, Gyawali CP, Katzka DA. AGA clinical practice update on reducing rates of post-endoscopy esophageal adenocarcinoma: commentary. Gastroenterology 2020; 159: 1533-1537
    Search in Google Scholar
  • 17 Wani S, Holmberg D, Santoni G. et al. Magnitude and time-trends of post-endoscopy esophageal adenocarcinoma and post-endoscopy esophageal neoplasia in a population-based cohort study: the Nordic Barrett’s esophagus study. Gastroenterology 2023; 165: 909-919
    Search in Google Scholar
  • 18 Wani S, Yadlapati R, Singh S. et al. Post-endoscopy esophageal neoplasia in Barrett’s esophagus: consensus statements from an international expert panel. Gastroenterology 2022; 162: 366-372
    Search in Google Scholar
  • 19 Whiteman DC, Appleyard M, Bahin FF. et al. Australian clinical practice guidelines for the diagnosis and management of Barrett’s esophagus and early esophageal adenocarcinoma. J Gastroenterol Hepatol 2015; 30: 804-820
    Search in Google Scholar
  • 20 Fitzgerald RC, di Pietro M, Ragunath K. et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut 2014; 63: 7-42
    Search in Google Scholar
  • 21 Weusten B, Bisschops R, Coron E. et al. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy 2017; 49: 191-198
    Search in Google Scholar
  • 22 Roumans C, van der Bogt R, Steyerberg E. et al. Adherence to recommendations of Barrett’s esophagus surveillance guidelines: a systematic review and meta-analysis. Endoscopy 2019; 52: 17-28
    Search in Google Scholar